Alterity Therapeutics Limited Cash Flow-to-Debt Ratio
Alterity Therapeutics Limited cash flow-to-debt ratio. Alterity Therapeutics Limited (PBN) has a Cash Flow-to-Debt Ratio of -1.12x as of June 2023, meaning its operating cash flow of €-5.06 Million could theoretically repay -1% of its total liabilities (€4.50 Million) in one year. See PBN financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Alterity Therapeutics Limited (2014–2025)
Cash flow-to-debt ratio of Alterity Therapeutics Limited from 2014 to 2025. Historical debt coverage capacity for Alterity Therapeutics Limited across 12 annual periods. Also explore PBN shareholders equity momentum to track the company's year-over-year net asset growth rate.
Alterity Therapeutics Limited Cash Flow-to-Debt Ratio by Year (2014–2025)
Alterity Therapeutics Limited cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Alterity Therapeutics Limited. For the full cash flow conversion analysis, see Alterity Therapeutics Limited (PBN) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.16x | €-11.45 Million | €3.62 Million | ▼ -36.0% |
| 2024 | -2.32x | €-12.61 Million | €5.43 Million | ▲ +47.8% |
| 2023 | -4.45x | €-20.04 Million | €4.50 Million | ▼ -112.5% |
| 2022 | -2.09x | €-12.34 Million | €5.89 Million | ▲ +62.4% |
| 2021 | -5.56x | €-17.33 Million | €3.12 Million | ▼ -62.6% |
| 2020 | -3.42x | €-9.43 Million | €2.76 Million | ▲ +17.8% |
| 2019 | -4.16x | €-13.95 Million | €3.36 Million | ▼ -76.1% |
| 2018 | -2.36x | €-6.25 Million | €2.64 Million | ▲ +36.0% |
| 2017 | -3.69x | €-5.87 Million | €1.59 Million | ▼ -17.2% |
| 2016 | -3.15x | €-7.42 Million | €2.36 Million | ▲ +21.2% |
| 2015 | -4.00x | €-10.87 Million | €2.72 Million | ▼ -16.7% |
| 2014 | -3.42x | €-13.54 Million | €3.95 Million | — |